MEIRAGTX
"MEIRAGTX" is a word mark owned by MeiraGTx Limited, filed at the USPTO on January 30, 2025. It is registered and covers classes 1, 5, 40 and 42.
- Status
- Registered
- Since February 17, 2026
- Filed
- January 30, 2025
- Registered
- February 17, 2026
- Expires
- Not recorded
- Application no.
- 99023559
- Registration no.
- 8140892
- Office
- USPTO
- United States Patent and Trademark Office
- Mark type
- Word mark
- 4 classes
Who owns MEIRAGTX
The owner and representative on file with the office.
Owner
MeiraGTx Limited
London, United Kingdom
Representative
Michael J. Leonard
Fox Rothschild LLP
What the mark covers
The products and services MEIRAGTX is filed for, grouped by Nice class.
chemical additives, namely, chemical auxiliary agents, carriers, and substances, all for use in the manufacture of pharmaceutical preparations
pharmaceutical products for use in gene therapy; pharmaceutical preparations and substances for the treatment of neurological and neurodegerative diseases, ocular diseases and rare diseases, in the nature of rare kidney diseases, rare cardiovascular diseases, rare hepato-gastro-enterological diseases, rare immunodeficiencies, developmental defects, neuromuscular diseases, rare neurological diseases, rare cardiovascular diseases, rare lung diseases, rare bone diseases, rare sensory disorders, rare skin diseases, rare diseases of connective tissue, rare endocrine diseases, rare hereditary metabolic diseases, rare nonmalignant hematologic disorder, salivary gland conditions, oncology, autoimmune conditions, ageing, metabolic disease, obesity; auxiliary agents for pharmaceutical preparations, namely, small molecule compounds for use as drug delivery agents in pharmaceuticals; carriers for pharmaceutical preparations, namely, drug delivery agents consisting of compounds that facilitate delivery of pharmaceuticals; substances for pharmaceutical preparations, namely, namely, anti-infectives, anti-inflammatories, antibacterial pharmaceuticals, antibiotics, antifungal preparations, and antivirals; pharmaceutical preparations for the prevention and treatment of cardiovascular diseases; dermatological pharmaceutical preparations and substances; pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastro-intestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases and conditions; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical preparations and substances for ophthalmological use; pharmaceutical preparations and substances for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and treatment of allergies; pharmaceutical preparations and substances for the prevention and treatment of bone diseases, salivary gland conditions, oncology, autoimmune conditions, aging, metabolic disease, and obesity; biological preparations for use in cell cultures for medical purposes
Custom manufacture of human therapeutics, pharmaceuticals, biologicals and biopharmaceuticals
scientific research in the field of genetics, gene therapy and genetic engineering; genetic testing for scientific research purposes; scientific advisory services relating to gene therapy research; scientific, biological, pharmaceutical and medical research services; laboratory research in the fields of genetics, drug development, biotechnology, microbiology and molecular biology; biochemical and biotechnological analysis services
What has happened so far
Steps recorded by the USPTO, newest first.
- Notice of registration confirmation emailed
- Registered-principal register
- Official gazette publication confirmation e-mailed
- Published for opposition
- Notification of notice of publication e-mailed
- Approved for pub - principal register
- Examiner's amendment entered
- Notification of examiners amendment e-mailed
- Examiners amendment e-mailed
- Examiners amendment -written
10 earlier steps on the official record.
About MEIRAGTX
Who owns the trademark "MEIRAGTX"?
The USPTO trademark "MEIRAGTX" (application 99023559) is owned by MeiraGTx Limited.
What is the status of "MEIRAGTX"?
Its status at the USPTO is: registered.
When was "MEIRAGTX" registered?
It was registered on February 17, 2026.
Get this data via the API
Everything on this page comes from the Signa API. Pull MEIRAGTX and marks like it into your own product with one request.
GET/v1/trademarks/{id}The full record: owners, classes, dates and images
GET/v1/trademarks/{id}/eventsEvery step in the office history
GET/v1/proceedings?trademark_id={id}Oppositions and cancellations against the mark
ID=tm_019d2a69-439f-7066-9e05-8e46e9d9620c
curl https://api.signa.so/v1/trademarks/$ID \
-H "Authorization: Bearer $SIGNA_API_KEY"{
"id": "tm_019d2a69-439f-7066-9e05-8e46e9d9620c",
"object": "trademark",
"mark_text": "MEIRAGTX",
"status": {
"primary": "active",
"stage": "registered"
},
"office_code": "US",
"application_number": "99023559",
"filing_date": "2025-01-30",
"nice_classes": [
1,
5,
40,
42
],
"owners": [
{
"name": "MeiraGTx Limited",
"entity_id": null
}
]
}